Cyclosporine (Vevye)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Dry Eye Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Vevizye (ciclosporin 0.1% eye drops solution, CyclASol / Vevye) for moderate to severe dry eye disease in adults not responding to tear substitutes
Product first approved 2024eyewire.news

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Dry Eye Disease
NCT04523142 · Novaliq GmbH
2021-01-04 – 2022-05-23 · Dry Eye Disease (DED)
What this study did
Phase 2/3 (1)
Dry Eye Disease
NCT03292809 · Novaliq GmbH
2017-10-19 – 2018-06-20 · Dry Eye Disease
What this study did
Phase 2 (1)
Dry Eye Disease
Phase 1 (1)
Other / comorbidity
NCT02113293 · Novaliq GmbH
2014-03 – 2014-05 · Healthy
What this study did
Phase 4 (5)
Dry Eye Disease
NCT07553455 · Canyon City Eyecare
2026-04-03 – 2026-12-31 · Dry Eye
What this study did
NCT07025811 · Hoffmann-La Roche
2025-07-09 – 2026-07-16 · Dry Eye Disease
What this study did
NCT06329661 · Novaliq GmbH
2024-04-22 – 2025-07-30 · Dry Eye Disease, Endothelial Cell
What this study did
Other / comorbidity
NCT07224529 · University of Alabama at Birmingham
2026-06-01 – 2027-02-01 · Meibomian Gland Dysfunction (MGD)
What this study did
Early phase / not applicable (1)
Dry Eye Disease
NCT07904728 · Ocular Aesthetics, LLC dba Ocular Clinical Trials
2026-08-25 – 2027-04-15 · Dry Eye Disease (DED), Contact Lens Discomfort (CLD)
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Dry Eye Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cyclosporine (Vevye): this drugApprovedSmall moleculeCalcineurinPartial signalNo reviewed efficacy summary in this indication
Voclosporin (Lupkynis)
Approved(overall)
Small moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Extended-Release Tacrolimus (VI-0106)
Phase 3(overall)
Small moleculeCalcineurin
not yet graded(overall)
No reviewed efficacy summary in this indication
PL9643Phase 3PeptideMelanocortin receptorsPartial signal
NCT05201170: Co-primary sign endpoint (lissamine green staining) did not achieve statistical significance; in the unadjusted planned analyses neither co-primary reached significance missed
ReproxalapPhase 3Small moleculeReactive aldehyde species (RASP)not yet gradedNo reviewed efficacy summary in this indication
Nanosomal Tacrolimus
Phase 2(overall)
Small moleculeCalcineurin
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cyclosporine (Vevye) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Dry Eye DiseaseEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07553455 · CT.gov ↗
What to watch
2027 (3)
February 2027 (1)
Phase 4Meibomian Gland Dysfunction (MGD)Recruiting
Est. primary completion 2027-02-01 · NCT07224529 · CT.gov ↗
What to watch
March 2027 (2)
Early phase / not applicableDry Eye DiseaseRecruiting
Est. primary completion 2027-03-15 · NCT07904728 · CT.gov ↗
What to watch
Phase 4Dry Eye DiseaseNot yet recruiting
Est. primary completion 2027-03-31 · NCT07368595 · CT.gov ↗
What to watch

See the full readout calendar ↗